NorthWest Biotherapeutics Inc (NWBO)

[VuBru]

Thanks Dr. B - I do not see the new definition as a bad thing based on what has been posted. I do wonder though whether they will have enough information from published historical control trials to make legitimate comparisons of "real GBM" (new definition) in those trials to "real GBM" in the DCVAX trial in their planned primary analyses. I suppose if prior trials reported percentage of patients with different GBM subtypes, they might be able to weight each trial for "real GBM," but not sure how that would work.